Trial Profile
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs ASN 003 (Primary)
- Indications Carcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 17 May 2019 Status changed from active, no longer recruiting to discontinued.
- 10 Apr 2018 According to an Asana BioSciences media release, the data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
- 06 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.